Considering that noradrenergic (NAE) neurons of the locus coeruleus (LC) play significant roles in the formation of biological rhythms, pain, addictions, and mood disorders, we tested the effects of acute intracerebroventricular microinfusions of bupropion, an inhibitor of NA reuptake used in clinics as an antidepressant, on background spike activity on LC neurons in chloral hydrate anesthetized rats. Ten microliters of the solutions containing 0.001, 0.01, 0.1, 1.0, or 10.0 µmol bupropion were infused during 3 min; spike activity of single LC neurons identified according to the known characteristics was recorded extracellularly by glass microelectrodes. Microinfusions of 0.01 to 10.0 µmol bupropion suppressed background spiking of the above neurons in a dose-dependent manner. The normalized mean intensities and durations of inhibition were 17.3, 19.4, 26.3, and 41.1% and 1.4, 7.1, 12.4, and 18.3 min, respectively. The smallest dose (0.001 µmol) was ineffective. It is assumed that bupropion increases the NA level in proximity to NAE LC neurons. The actions of bupropion on other cerebral neuromodulatory systems need further examination. Inhibition of LC neuronal activity by bupropion can help to explain some acute, chronic, and side effects of this agent used in clinics for correction of mood disorders.
INTRODUCTION
The noradrenergic (NAE) neurons of the locus coeruleus (LC) play essential roles in the control of important biological phenomena such as sleep, cardiovascular control, depression, etc. [1] . The monoamine hypothesis of depression genesis was proposed in 1965; as was assumed, monoamines, noradrenaline (NA) in particular, are likely to be the key elements in the etiology and progression of depression. This hypothesis motivated researchers to elucidate the roles of monoamine neurotransmitters, serotonin (5-hydroxytryptamine, 5-HT), NA, and dopamine (DA), in the pathogenesis of depression. Further development of the catecholamine hypothesis proposed that depression may be related simply to a deficiency of catecholamines, mostly of NA [2] . However, both elevations and reductions in the level of NA or its metabolites have been demonstrated in the cerebrospinal fluid (CSF), plasma, and urine of depressed patients, and this made controversial the respective statements on the involvement of NA in the initiation of depression [3] .
According to the monoamine hypothesis on the etiology of depression, the LC plays a major role in the respective disorders [4] ; the deficiency of monoamines in the brain regions is the major factor for the development of depression, and most antidepressant drugs increase the synaptic availability of monoamines [5] [6] [7] . However, convincing evidence of a primary role of dysfunction of the specific monoamine brain systems in patients with major depressive disorders has not been found [5] .
Although the main effects of antidepressants were thought to be reflected in the activation of LC neurons, studies of LC neuronal activity revealed a paradoxical evidence of both decreased density of neurons and increased tyrosine hydroxylase activity [8, 9] . Chronic administration of some antidepressants can decrease background and burst evoked firing of LC neurons [10, 11] . Recently, West et al. reported that an antidepressant, paroxetine, increased LC neuronal activity in young rats [12] ; thus, it was shown that the effect of some antidepressants on LC neuronal activity may be unique.
As was reported, acute systemic administration of bupropion in rats inhibited LC NAE neuronal activity. This inhibition appeared unrelated to a direct action of bupropion on LC NAE neurons or to its modulatory action on other neurotransmitters in the brain regions. Metabolites of bupropion can alter neuronal activity of the above neurons [13] . Desipramine, an NA reuptake blocker, was found to inhibit LC neuronal activity, but the nature of such inhibitory effects exerted by the blocker itself or its metabolites was not convincingly interpreted [14] . In our recent study, we assumed that bupropion may increase the activity in the ventral tegmental area indirectly via inhibition of GABAergic neurons [15] .
We assume that inhibition of LC neuronal activity by bupropion is provided by the direct action of bupropion on NA receptors localized on the dendrites and/or soma of LC NAE neurons. This study was designed to test the effects of intracerebroventricular (ICV) acute microinfusions of bupropion on impulse neuronal activity in the LC and to evaluate the direct/indirect nature of the effect of this agent.
METHODS
Healthy male Wistar rats (Pasteur Institute, Iran; body mass 250-280 g) were used. Animals were housed three in a cage at a 12 h light/dark cycle (7:00 a.m. to 7:00 p.m.) and controlled temperature (22 ± 2°C) with food and water ad libitum. Animals were divided into seven groups: control, sham, and five groups microinfused with solutions containing different amounts of bupropion (n = 6 to 12 rats in each group). The rats were anesthetized with chloral hydrate (400 mg/kg, i.p.; the booster dose was about 10-15% of the initial dose) and secured in a stereotaxic instrument (Stoelting, USA). The body temperature was monitored continuously and maintained at ~37°C throughout the experiment. The bregma and interaural stereotaxic coordinates were measured for each rat, and the location of the opening for LC recording was determined according to the rat stereotaxic brain atlas [16] .
Single unit spike activity was recorded from LC neurons as described previously [17] . Briefly, after anesthesia and opening of the skull, a glass microelectrode (in vitro impedance 3-6 MΩ) filled with a 2% solution of Pontamine Sky Blue in 0.5 M sodium acetate was inserted in the brain into the region of LC localization (Bregma -9.84, ML 1.35, and DV 6.8 mm with respect to the bregma zero-zero plane) until single neuronal activity could be clearly detected. For all neuronal recordings, the criteria described earlier [18] [19] [20] [21] were taken into account. These criteria were the following; (i) long-lasting positive-negative waveform with a notch, (ii) biphasic excitation-inhibition responses to contralateral hind paw pinch, and (iii) regular background activity with a relatively low firing rate (0.5-5.0 sec -1 ). The units satisfying the mentioned criteria were recorded in the case of stable amplitude and firing rate. The recorded activity was filtered (bandpass 300-3000 Hz), amplified, digitized, and addressed to a PC computer (Electromodule 3111 data acquisition system, Http://www.sciencebeam. com/). Digitized data were displayed on an oscilloscope using NeuroComet software (Http:// www.sciencebeam.com). This software was also used for window discrimination of spikes and analysis of the activity. Peristimulus time histograms (PSTHs) for single units were plotted with 1-msec-long bins. Sensitization or desensitization of the recorded units was tested by contralateral hind paw compression. All units with no respective shifts were included in the analysis. Frequency graphs were also plotted for estimation of the firing rate stability.
The PSTHs extracted on-line or off-line were checked again by a blind-control person. Samples of spiking used for plotting PSTHs and current frequency graphs were 5 min long. In each record, the spiking stability was estimated within a 5-minlong interval, and a subsequent 10-min-long interval was used for baseline estimation. Forty-min-long recordings were used for assessing possible effects of infusions of artificial cerebrospinal fluid (ACSF) or the drug (bupropion), with cut-off on the 60th min.
For bupropion infusion, a 30-gauge stainless steel needle was connected to a 10 µl Hamilton syringe by a polyethylene tube. The needle was stereotaxically inserted into the right lateral ventricle. The drug vehicle (ACSF) or solutions containing different amounts of bupropion were injected by a microsyringe pump. The volumes of all injections were 10 µl, and the duration of infusion was 3 min. Concentrations of bupropion in the solutions used for microinfusions were 0.0001, 0.001, 0.01, 0.1, and 1.0 M; thus, the amounts of infused bupropion, considering the volume of infusions (10 µl), were 0.001, 0.01, 0.1, 1.0, and 10.0 µmol, respectively.
After the experiments, all animals were deeply anesthetized and perfused with 10% formalin phosphate-buffered solution. The brains were removed and fixed in the perfusion solution. Coronal 40-µm-thick sections were prepared on a microtome and stained by Fast Cresyl Violet. The trajectory path and location of the infusion cannula tip were verified under a light microscope. The rats with unsuccessful injections were excluded from the analysis.
Drugs, chemicals, and equipment used in our study included bupropion, formalin, Pontamine Sky Blue, Fast Cresyl Violet, chloral hydrate (SigmaAldrich, USA), sodium acetate and sodium chloride (Merck, Germany), polyethylene microtubes (A-M system, USA), and Hamilton microsyringes (Hamilton Bonaduz AG, Switzerland).
Numerical data of the firing rate of single units were analyzed using oneway analysis of variance (ANOVA). Analysis of the effect of different doses of the drug was carried out using ANOVA and the Tukey's posthoc test. P < 0.05 indicated the least statistical significance in intergroup comparisons. Numerical data are shown below as means ± s.d.
RESULTS
An example of the typical LC neuronal spike is shown in Fig. 1 A; the upper and lower levels of window discrimination are also seen. The absolute amplitude of the extracellularly recorded single unit spikes varied between 40 and 250 µV. A brief pinch of the contralateral paw served as the test for verifying that the neuron belongs to the LC nucleus. The paw pinch elicited a burst of activity in single units in chloral hydrate-anesthetized rats; such bursts were accompanied by a period of afterinhibition (Fig. 1 B) . A greater pressure could elicit a more significant increase in the burst firing rate with no sensitization. Figure 2A is a typical graph for the firing rate of an LC neuron in an anesthetized rat of the control group. In this case, the neuron firing rate was 1.88 ± ± 0.05 sec -1 . As can be seen, variations of the firing rate of background activity are minimum; the stationarity of this activity is a typical feature of LC NAE neurons. For testing of the microinfusion volume effect on LC neuronal activity, the drug vehicle (ACSF) was microinjected in the sham group (10 µl/3 min). Figure 2B shows a typical example of the neuronal firing rate observed under such conditions. In this sample, the mean firing rate within the pre-microinfusion period (minutes 1 to 10) was 1.90 ± 0.04 sec -1 , while that within the post-microinfusion interval (minutes 14 to 45) was 1.87 ± 0.04 sec -1 . Analysis of the firing rates within the pre-and post-microinfusion of ACSF showed that there was no statistically significant difference between these values (t-test, P = 0.31). Thus, microinjections of 10 µl of ASCF exerted negligible effects on background firing of LC neurons.
In the control group (n = 8), 24 LC neurons were recorded, and 26 units were recorded in the sham group (n = 7). The average firing rate of controlgroup neurons was 2.54 ± 1.11sec -1 , while that in the sham group was 2.65 ± 1.26 sec -1 . In all records, there was no significant difference between the premicroinfusion and post-microinfusion periods. Figure 3 shows the effects of different ICVinfused bupropion doses (0.001, 0.01, 0.1, 1.0, and 10.0 µmol) on the background firing rate of five LC neurons. It is obvious that bupropion-induced effects are clearly dose-dependent. Doses of 0.01 to 10.0 µmol provided noticeable inhibition of LC activity, while there was no significant inhibitory effect of the lowest bupropion dose (0.001 µmol).
The significant dependence of the intensity of bupropion-induced suppression of background impulse activity generated by LC NAE neurons and the time course of this inhibition are more clearly visible on a graph of normalized changes in this activity for the entire examined group. The effects of infusions of 0.001, 0.01, 0.1, 1.0, and 10.0 µmol bupropion were examined on 22, 28, 23, 29, and 34 LC neurons, respectively. The mean normalized intensities of decreases in the rate of background firing were 1.41 ± 0.12, 7.14 ± ± 4.85, 12.40 ± 3.11, and 18.30 ± 5.45% for the doses of infused bupropion of 0.01, 0.1, 1.0, and 10.0 µmol, respectively (Fig. 4, 2-5) . In all cases, the firing rates of LC neurons within the pre- 
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Averaged normalized bupropion-induced changes, %, in the firing rate of the examined LC neurons. The mean firing rates within the pre-infusion period were taken in each case as 100%.
Other indications are similar to those in Fig. 3 . The duration of inhibition of the activity was calculated by repeated-measure ANOVA for determination of the differences between points. The maximum inhibition was estimated as the average in the experimental groups. The mean firing rates within the pre-infusion period were assumed as 100%. microinfusion period were taken as 100%. The maxima of bupropion-evoked inhibition of spiking were also shifted with increase in the dose of the infused drug, and the total duration of inhibition increased (Fig. 4) . The duration of suppression of impulsation was calculated by repeated-measure ANOVA for determination of the differences be-tween points. The averaged durations of such suppression at the above-mentioned bupropion doses were 1.41 ± 1.20, 7.14 ± 4.85, 12.40 ± 3.11, and 18.00 ± ± 4.45 min, respectively. The intergroup differences of these walues were significant. These data are summarized in the diagrams of Fig. 5 . The smallest infused bupropion dose (0.001 µmol) provided no significant effect on the LC neuronal firing rate (P = 0.23).
DISCUSSION
Our electrophysiological data demonstrated that acute ICV microinfusions of bupropion, an NA reuptake inhibitor frequently qualified as an atypical antidepressant, are capable of significantly suppressing background neuronal activities of single LC neurons in a clear dose-dependent manner. No dramatic sensitization or desensitization in the influence of bupropion on LC neurons was observed, and this agent could inhibit the above background neuronal activity for a few minutes.
Hypotheses on the mechanisms by which antidepressants, such as bupropion, can produce inhibition of LC neuronal activity are controversial. The main suggested mechanism for inhibition of LC neurons by antidepressants is the involvement of NA reuptake blocking in the vicinity of the dendritic tree and/or soma of these neurons. Blocking of this reuptake process by bupropion is consistent with a strong inhibitory action on LC firing that is exerted via stimulation of somatodendritic alpha-2 NA receptors localized on LC neurons. The elevated NA level in close proximity to somatodendritic synapses results in more intense binding of NA to alpha-2 receptors and provides hyperpolarization of LC neurons. This effect can be mimicked by clonidine (an alpha 2-adrenoceptor agonist) [22] [23] [24] . Not only NA reuptake inhibitors, but also other inhibitors influencing biogenic amines, in particular 5-HT reuptake inhibitors, can suppress spiking of LC neurons. The respective findings revealed that serotonergic receptors are localized on the LC cell bodies, and the action of 5-HT within the regions adjacent to these receptors inhibits LC activation [25] . Therefore, any agent that can increase the NA concentration in the synaptic environment can inhibit LC impulse activity. Monoamine oxidase (MAO) inhibitors can also suppress spiking of LC neurons by increasing the NA level [26] .
Observations made in our study on the inhibitory action of acute ICV infusions of bupropion are consistent with what other investigators found after administration of antidepressant drugs [27] [28] [29] . There were reports, however, that chronic administrations of some antidepressants did not decrease background or sensory-evoked LC neuronal activity due to manifestations of tolerance under conditions of chronic action of these drugs [28, 30, 31] . It should be taken into account that tolerance could not significantly develop in our experiments where acute action of bupropion was tested. The involvement of NA receptors of LC neurons in the pathogenesis of major depression (MD) has been studied in post mortem cases. Based on the data of many researches, an abnormal state of the central NAE system was proposed to play an important role in the pathophysiology of this disease. Alpha-2 adrenoreceptors throughout the LC were found to be significantly elevated in patients suffering from MD compared to the matched control subjects [32] . Increased levels of tyrosine hydroxylase and decreased levels of the NA transporter (NAT) imply NA deficiency in the LC related to MD. The NAT is a membrane protein responsible for termination of the action of synaptic NA and is a site of action for many drugs used to treat MD [33] .
The mechanism of reduction of the LC neuronal firing rate due to acute ICV infusions of bupropion is not fully understood. There is well-known evidence that the effect of bupropion (a rapid and significant drop in the firing rate of LC cells) is antagonized by yohimbine and piperoxane (alpha-2 adrenergic antagonists), implying that there is ultimately activation of alpha-2 receptors in the rat brain [34] . An indirect mechanism of bupropion for suppression of LC firing does not completely explain the effect of this drug on LC neurons because inhibition of NA uptake can be demonstrated in vivo only at tenfoldhigher doses [35] . At the same time, our findings on the action of bupropion are consistent with what other researchers reported after acute administration of antidepressant drugs [27-29, 36, 37] .
The acute antidepressant effect of bupropion is more closely associated with its action on the firing rate of NAE LC neurons than with its effect on midbrain mesolimbic dompaminergic neurons. These results confirm previous findings [10, 11, 38] .
Thus, we found that ICV microinfusions of the atypical antidepressant bupropion inhibit background impulse activity of LC-NAE neurons in chloral hydrate-anesthetized rats in a dosedependent manner. A detailed understanding of the pharmacological properties of bupropion should help to establish the true efficacy of its action on NA uptake. Potent interactions of bupropion with cholinergic, histaminergic, serotonergic, and dopaminergic systems in the brain should be examined for adequate interpretation of the effects of this drug. At the same time, our data add some information helping to explain acute, chronic, and side effects of bupropion used in clinics for correction of mood disorders.
